ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "cytokines"

  • Abstract Number: 1700 • ACR Convergence 2022

    IL-21/STAT3 Pathway Mediated Th2-like Vδ2 T Cells Promote Plasmablasts Differentiation in IgG4-Related Disease

    Jieqiong Li1 and Wen Zhang2, 1Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, 2Peking Union Medical College Hospital, Beijing, China

    Background/Purpose: To explore the phenotype and role of gamma delta (γδ) T cells in the pathogenesis of IgG4-related disease (IgG4-RD), focusing on the effect on…
  • Abstract Number: 0569 • ACR Convergence 2022

    Cytokine Storm Susceptibility Factors IL-18 and Cytotoxic Impairment Converge on Pathologic CD8 T-cell Hyperactivation

    Emily Landy1, Scott Canna2, Paul Tsoukas3, Vinh Dang2 and Jemy Varghese2, 1University of Pittsburgh, Pittsburgh, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Mounting evidence suggests partial defects in cytotoxicity-related genes may promote hyperinflammation in Macrophage Activation Syndrome (MAS) patients, who uniformly have highly-elevated IL-18. In mice,…
  • Abstract Number: 0806 • ACR Convergence 2022

    Long-term Effectiveness of Sublingual Polybacterial Vaccines in Patients with Systemic Autoimmune Disease and Active Pharmacological Immunosuppression

    Inés Pérez Sancristóbal1, María Paula Álvarez Hernández2, Silvia Sanchez - Ramon3, Cristina Martinez4, Eduardo de la Fuente3, Concepcion Morado4, Dalifer Freites Nuñez2, Benjamin Fernandez Gutierrez5 and Gloria Candelas4, 1Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain, 2Hospital Clínico San Carlos, Madrid, Spain, 3Department of Clinical Immunology, IML and IdSSC, Hospital Clínico San Carlos, Madrid, Spain, 4Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 5Hospital Clínico San Carlos, Rheumatology Deparment, Madrid, Spain

    Background/Purpose: Infections in patients with systemic autoimmune disease (SAD) are associated with immune dysfunction, disease activity and immunosuppression. Synthetic and biologic disease-modifying drugs (DMARDs) have…
  • Abstract Number: 1729 • ACR Convergence 2022

    SLAMF4+ CCR5+ Effector Memory CD4+ T Cells Are Polyfunctional, Resistant to Exhaustion, and Expanded in Rheumatoid Arthritis

    Mégane Lacaud1, Houda-Ghozlane Bouzidi1, Magali Breckler2, Delphine Lemeiter2, Johanna Sigaux3, Luca Semerano4, Marie-Christophe Boissier5, Natacha Bessis6 and Jerome Biton7, 1Sorbonne Paris Nord University, Inserm U1125, Bobigny, France, 2Sorbonne Paris Nord University, Inserm UMR1125, Bobigny, France, 3Avicenne Hospital, Sorbonne Paris Nord University, Inserm UMR1125, Bobigny, France, 4Hopital Avicenne - AP-HP, Sorbonne Paris Nord University, INSERM UMR1125, Bobigny Cedex, France, 5INSERM UMR 1125, Sorbonne Paris Nord University,Rheumatology Dpt, APHP, GHUPSSD, Avicenne Hosp, Bobigny, France, 6INSERM 1125 and University Sorbonne Paris Nord, Bobigny, France, 7INSERM UMR 1125, Sorbonne Paris Nord University, Bobigny, France

    Background/Purpose: CD4+ Foxp3- conventional T cells (Tconv) play a key role in the inflammatory process involved in rheumatoid arthritis (RA). Usually, chronic stimulation of T…
  • Abstract Number: 0581 • ACR Convergence 2022

    Mutants Improving Stability Enhance the Potency of Treg-Selective IL-2 Mutein for the Treatment of Autoimmune Disorders

    Yingying Hu1, Hu Ge1, Yuxi Yan1, Yun Zhang2, Xiaoxing Huang1, Zhenna Gao2, Yiming Kou2, Mi Ye2, Lei Zhou1, Siyuan Shao1, Bowei Yin1, Zhenzhen Li1, Yayuan Fu1, Wenqing Yang1, Zhuoxiao Cao1 and Renhong Tang1, 1Simcere Pharmaceutical Group, Shanghai, China, 2Simcere Pharmaceutical Group, Nanjing, China

    Background/Purpose: Low-dose IL-2 with enhanced sensitivity to Treg cells has been proved to be safe and efficacious in multiple autoimmune disorders (AIDs) including SLE, RA,…
  • Abstract Number: 0985 • ACR Convergence 2022

    S100 Serum Protein Expression Is a Useful Indicator of HCQ Treatment Efficacy in SLE

    Risa Wakiya1, Hiromi Shimada1, Kiyo Ueeda2, Shusaku nakashima1, Mikiya Kato1, Taichi Miyagi1, Yusuke Ushio3, Koichi Sugihara1, Rina Mino3, mao mizusaki4, Kanako Chujo5, Tomohiro Kameda1 and Hiroaki Dobashi6, 1Kagawa University, Miki-cho, Kita-gun, Japan, 2Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, 3Kagawa university, Kagawa, Japan, 4Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, 5Kagawa University, Miki, Kita District, Kagawa, Japan, 6Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan

    Background/Purpose: It is known that type 1 IFN and proinflammatory cytokines are associated with the pathogenesis of systemic lupus erythematosus (SLE). Recently, the S100 protein,…
  • Abstract Number: 1736 • ACR Convergence 2022

    IL-23 Signaling Induces Autoimmune Disease Genes in Mucosal-Associated Invariant T Cells

    Tharshana Stephen1, Ambre Dangien1, Claire Leloup1, Ikram Mezghiche1, Laetitia Camard1, Hanan Yahia-Cherbal1, Vincent Guillemot2, Natalia Pietrosemoli1, Hélène Lopez-Maestre1, Julie Marsande1, Milena Hasan1, Dan Cua3, Anne Fourie4, Carrie Greving5, Raphaelle Parker6, Barbara Joyce Shaikh7, Bénédicte Oulès8, Sarah Guégan8, Sélim Aractingi8, Elisabetta Bianchi1 and Lars Rogge1, 1Institut Pasteur, Paris, France, 2Institut Pasteur, Paris, Ile-de-France, France, 3Janssen Research and Development, LLC, Spring House, PA, 4Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, CA, 5Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, 6Janssen Research & Development, Janssen-Cilag, Paris, France, 7Janssen Research & Development, LLC, San Diego, CA, 8Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: Genome-wide association studies and mouse models of autoimmune disease have demonstrated an important role of the IL-23 signaling pathway in the pathogenesis of axial…
  • Abstract Number: 0583 • ACR Convergence 2022

    Toll-Like Receptor Ligands Stimulated Monocyte-Derived Langerhans Cell-Like Dendritic Cells Induce Psoriasis-Related Molecules, IL-23 and Delta-Like-4

    Rei Takahashi1, Kohei Maeda1, Toshihiro Tanioka1 and Takeo Isozaki2, 1Division of Pathogenesis and Translational Medicine, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan, 2Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

    Background/Purpose: Monocyte-derived Langerhans cell-like dendritic cells (Mo-LCs) are involved in epidermal disorders such as psoriasis in murine models. However, the roles of Mo-LCs in the…
  • Abstract Number: 1048 • ACR Convergence 2022

    Nailfold Capillaroscopy and Candidate Biomarker Levels in Systemic Sclerosis-associated Pulmonary Hypertension, Profiling of Non-invasive Markers: A Cross Sectional Study

    Jacqueline Lemmers1, Arjan van Caam2, Brigit Kersten2, Els Ende, van den2, Hanneke KNAAPEN2, Arie Dijk, van2, Wanda Hagmolen of ten Have2, Frank van den Hoogen2, Hans Koenen2, Sander van Leuven3, wynand Alkema4, Ruben Smeets2 and Madelon Vonk5, 1Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands, 2Radboudumc, Nijmegen, Netherlands, 3Radboud University, Nijmegen, Netherlands, 4Hanze University, Groningen the Netherlands, Dept. Data Science for Life Sciences & Health, Groningen, Netherlands, 5Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands

    Background/Purpose: Pulmonary hypertension (PH) is one of the leading causes of death in Systemic Sclerosis (SSc). Early detection and treatment of PH in SSc is…
  • Abstract Number: 1741 • ACR Convergence 2022

    Mutated Nod2 Controls T Cell Function and Promotes Uveitis in a Blau Syndrome Mouse Model

    Leah Huey1, Kylie Koney1, Emily Vance1, Chia-Feng Tsai2, Rosalie K. Chu2, Marina A. Gritsenko2, Ellen Lee1, Holly Rosenzweig1 and Ruth Napier1, 1Oregon Health & Science University and VA Portland Health Care System, Portland, OR, 2Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA

    Background/Purpose: Mutations in the microbial signaling molecule NOD2 cause granulomatous uveitis, arthritis, and dermatitis in Blau Syndrome. We previously showed a novel role for Nod2…
  • Abstract Number: 0584 • ACR Convergence 2022

    Non-Clinical Evaluations of Deucravacitinib and Janus Kinase Inhibitor Specificity in Inflammatory or Homeostatic Pathways

    Brandon Johnson, Jennifer Koenitzer, Peter Schafer and Ian M. Catlett, Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: Deucravacitinib is a selective inhibitor of tyrosine kinase 2 (TYK2) that has shown clinical efficacy in psoriasis, PsA, and SLE. Deucravacitinib is an allosteric…
  • Abstract Number: 1109 • ACR Convergence 2022

    High Interleukin-13 Level Is Associated with Disease Stability in Interstitial Lung Disease

    Elena Joerns1, David Karp1, Jeffrey Sparks2, Traci Adams1, Una Makris3 and Chad Newton1, 1UT Southwestern, Dallas, TX, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3UT Southwestern Medical Center and Dallas VA, Dallas, TX

    Background/Purpose: Interstitial lung disease (ILD) is a disease of lung parenchyma manifesting with inflammation and fibrosis. Interstitial lung disease (ILD) is a frequent complication of…
  • Abstract Number: 1745 • ACR Convergence 2022

    Effects of Excess IL-18 in Mixed Inflammatory Environments

    Vinh Dang1, Jemy Varghese1, Emily Landy2, Lauren Van Der Kraak2, Leonardo Huang1, Anastasia Frank-Kamenetskii1 and Scott Canna1, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Interleukin 18 (IL-18) is an inflammasome-activated, IL-1 family cytokine that canonically induces interferongamma (IFNg). IL-18 activity is potently inhibited by a soluble, IFNg-inducible antagonist,…
  • Abstract Number: 0585 • ACR Convergence 2022

    Baricitinib Inhibits Proinflammatoly Cytokine Production, Proliferation and Cell Migration in Human Lung Fibroblasts

    Takeo Isozaki1, Rei Takahashi2, Kohei Maeda2, Toshihiro Tanioka2, Kunika Shimizu3, Kazutaka Kawamori3, Noriko Konishi4, Shinichiro Nishimi3, Sho Ishii3, Kuninobu Wakabayashi3 and Tsuyoshi Kasama3, 1Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, 2Division of Pathogenesis and Translational Medicine, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan, 3Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Japan, 4Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction. Baricitinib is a selective small molecule inhibitor of JAK 1…
  • Abstract Number: 1141 • ACR Convergence 2022

    Consequences of SLE Heterogeneity on the Epigenome and the Drivers Behind

    Olivia Castellini-Pérez1, Athina Spiliopoulou2, Guillermo Barturen1, Andrii Iakovliev2, Manuel Martinez-Bueno1, Elena Carnero-Montoro1 and Marta Alarcon-Riquelme1, 1Center for Genomics and Oncological Research (GENYO), Granada, Spain, 2University of Edinburgh, Edinburgh, Scotland, United Kingdom

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a prototypic systemic autoimmune disease characterized by a complex aetiology and heterogenous symptomatology which has been recently dissected using…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology